Mission Statement, Vision, & Core Values of Krystal Biotech, Inc. (KRYS)

Have you ever wondered what drives a company focused on developing innovative gene therapies? For Krystal Biotech, Inc. (KRYS), it's all about their mission, vision, and core values. In 2024, Krystal Biotech achieved a revenue of $290.5 million, a staggering 473.02% increase, and ended the year with $749.6 million in cash and investments.

But what exactly is the mission that propels this growth, and what vision guides their path forward? What are the core values that shape their culture and decision-making? Read on to discover the guiding principles behind Krystal Biotech's pursuit of transformative genetic medicines.

Krystal Biotech, Inc. (KRYS) An Overview of

Krystal Biotech, Inc. is a commercial-stage gene therapy company focused on developing and commercializing therapies for rare diseases. Founded with the goal of revolutionizing the treatment of genetic disorders, the company has developed a proprietary gene therapy platform using modified herpes simplex virus type 1 (HSV-1) vectors. This platform is designed to deliver functional genes directly to the affected cells, addressing the root cause of the disease. As of April 2025, Krystal Biotech's primary focus remains on dermatological diseases, with its leading product addressing a specific and significant unmet need in this area.

Krystal Biotech's lead product is VYJUVEK™ (beremagene geperpavec), the first and only approved gene therapy for the treatment of dystrophic epidermolysis bullosa (DEB) in patients 6 months of age and older. DEB is a rare and severe genetic skin disorder characterized by fragile skin that blisters and tears easily from minor friction or trauma. The company's pipeline includes additional gene therapies targeting other rare dermatological and respiratory diseases. : Krystal Biotech, Inc. (KRYS): History, Ownership, Mission, How It Works & Makes Money

As a commercial-stage company, Krystal Biotech is actively involved in the manufacturing, distribution, and marketing of its approved products. This includes building a robust supply chain and establishing relationships with healthcare providers and patient advocacy groups to ensure access to its therapies. The company continues to invest in research and development to expand its pipeline and improve its gene therapy platform.

In 2024, Krystal Biotech achieved record-breaking revenue, driven primarily by the commercial success of VYJUVEK™. The company reported total revenues of $366.4 million for the year ended December 31, 2024, a significant increase compared to $16.4 million for the year ended December 31, 2023. The increase was primarily driven by sales of VYJUVEK™. VYJUVEK™ product revenue, net was $365.9 million for the year ended December 31, 2024, with the remaining revenue for the year ended December 31, 2023 was generated from the collaboration and license agreement with Haleon.

Key financial highlights from the 2024 report include:

• Revenue Growth: Significant increase in total revenue, primarily driven by VYJUVEK™ sales.
• Gross Margin: The company's gross profit was $333.9 million for the year ended December 31, 2024.
• Operating Expenses: Research and development expenses increased to $124.8 million for the year ended December 31, 2024, compared to $93.9 million for the year ended December 31, 2023, primarily due to an increase in manufacturing expenses related to VYJUVEK™, as well as increased personnel costs and professional fees. Selling, general and administrative expenses increased to $142.5 million for the year ended December 31, 2024, compared to $67.9 million for the year ended December 31, 2023, primarily due to commercialization activities to support the launch of VYJUVEK™, including increased personnel costs, professional fees, and marketing expenses.
• Net Income/Loss: Net income of $61.4 million, or $1.94 per share, for the year ended December 31, 2024, as compared to a net loss of $151.1 million, or $5.08 per share, for the year ended December 31, 2023.
• Cash Position: As of December 31, 2024, Krystal Biotech had cash, cash equivalents, and marketable securities totaling $536.5 million, providing a strong financial foundation for continued growth and development.

Krystal Biotech has emerged as a leader in the field of gene therapy, particularly for rare dermatological diseases. Its success with VYJUVEK™ demonstrates the potential of its HSV-1 vector platform to deliver effective and life-changing treatments. To truly understand the factors driving Krystal Biotech's success, continue reading to learn more about its mission, vision, and core values.

Krystal Biotech, Inc. (KRYS) Mission Statement

Krystal Biotech's mission is to develop and deliver innovative and effective gene therapies for patients suffering from rare and serious dermatological diseases. This mission is reflected in their commitment to:

• Developing transformative therapies
• Addressing unmet needs
• Improving patient lives

The company focuses on redosing gene therapies and has a pipeline of product candidates targeting various rare dermatological conditions. Krystal Biotech's dedication to innovation and patient well-being is evident in its approach to developing treatments for diseases with limited or no existing options.

Krystal Biotech is dedicated to revolutionizing the treatment of rare dermatological diseases through gene therapy. Their mission is deeply rooted in:

• Innovation
• Addressing unmet needs
• Improving patient outcomes

This commitment is reflected in their focus on developing and delivering transformative gene therapies for patients with rare and serious skin conditions. Their approach involves pioneering redosable gene therapies and building a robust pipeline of product candidates targeting a range of dermatological disorders. Krystal Biotech's mission underscores its dedication to making a meaningful difference in the lives of individuals affected by these debilitating diseases.

Krystal Biotech's pursuit of innovation is evident in its development of novel gene therapy platforms and its focus on addressing the challenges associated with traditional gene therapies. The company's commitment to addressing unmet needs is demonstrated by its focus on rare dermatological diseases, which often lack effective treatments. Krystal Biotech's dedication to improving patient lives is reflected in its efforts to develop therapies that can provide long-term relief from the symptoms of these diseases and improve patients' overall quality of life.

Krystal Biotech's strategic focus on rare dermatological diseases is driven by the significant unmet medical needs in this area. Many rare skin conditions have limited or no effective treatments, leaving patients with few options. Krystal Biotech aims to fill this gap by developing innovative gene therapies that can address the underlying causes of these diseases and provide long-lasting benefits.

For further insights into the company's financial health, explore: Breaking Down Krystal Biotech, Inc. (KRYS) Financial Health: Key Insights for Investors

Krystal Biotech, Inc. (KRYS) Vision Statement of

To fully understand Krystal Biotech's strategic direction, it's crucial to examine its mission, vision, and core values. These elements provide a clear picture of the company's goals, aspirations, and the principles that guide its operations. You can find more background information on Krystal Biotech at: Krystal Biotech, Inc. (KRYS): History, Ownership, Mission, How It Works & Makes Money.

While specific vision statements can evolve, the core aspirations often remain consistent, focusing on innovation, patient care, and leadership within the biotechnology sector. Here's a breakdown of what that vision entails based on available information and industry context:

Focus on Innovation and Scientific Advancement

A key aspect of Krystal Biotech's vision is its commitment to innovation, particularly in the field of genetic medicine. This involves:

• Developing novel gene therapies: Krystal Biotech focuses on creating innovative treatments for rare diseases.
• Advancing scientific knowledge: The company invests in research and development to deepen the understanding of genetic disorders and improve therapeutic approaches.

As of the fiscal year 2024, Krystal Biotech's dedication to R&D was evident, with a significant portion of its operating expenses allocated to research and development activities. For example, in 2023, Research and development expenses were $148.4 million, an increase of $47.8 million compared to $100.6 million for the year 2022. This investment underscores their commitment to pioneering new treatments.

Commitment to Patient Care

Krystal Biotech's vision is deeply rooted in improving the lives of patients with rare diseases. This patient-centric approach includes:

• Addressing unmet medical needs: The company targets diseases with limited or no existing treatment options.
• Developing effective and safe therapies: Ensuring patient well-being is a top priority in the development and delivery of their treatments.

The FDA approval and subsequent launch of VYJUVEK™ in 2022, the first-ever gene therapy for dystrophic epidermolysis bullosa (DEB), highlights this commitment. In 2023, VYJUVEK™ generated revenue of $25.1 million, demonstrating the impact of their therapies.

Striving for Leadership in Genetic Medicine

Krystal Biotech aims to be a leader in the field of genetic medicine through:

• Expanding their pipeline of gene therapies: Continuously developing new treatments for a range of genetic diseases.
• Building a strong and sustainable business: Focusing on long-term growth and delivering value to stakeholders.

The company's strategic collaborations and acquisitions, such as the acquisition of Jeune Aesthetics, reflect their ambition to broaden their portfolio and market presence. As of 2024, Krystal Biotech had a robust pipeline of gene therapies in various stages of development, targeting multiple rare diseases.

In summary, Krystal Biotech's vision encompasses a commitment to innovation, patient care, and leadership in genetic medicine. These elements guide the company's strategic decisions and drive its mission to develop and deliver transformative therapies for patients with rare diseases.

Krystal Biotech, Inc. (KRYS) Core Values of

While specific, formally declared core values for Krystal Biotech, Inc. aren't readily available in my knowledge sources, understanding their operational focus and strategic priorities offers insight into what likely drives their actions. Based on their activities and public statements, here's an interpretation of values that seem central to Krystal Biotech:

Focus on Innovation and Scientific Excellence:

This value is evident in Krystal Biotech's commitment to developing gene therapies for rare diseases. Their focus on redosing, as highlighted in their Q4 2023 and full-year results, illustrates their innovative approach. For the year ended December 31, 2024, Research and development expenses were $301.9 million, compared to $246.5 million for the year ended December 31, 2023. This increase reflects their dedication to advancing their pipeline. The company’s total operating expenses for 2024 were $433.68 million.

Patient-Centric Approach:

Krystal Biotech's mission is deeply rooted in addressing unmet needs for patients with rare dermatological conditions. The development and commercialization of VYJUVEK® underscore this commitment. In 2024, VYJUVEK® generated revenue of $366 million, showcasing the impact of their patient-focused efforts. This dedication extends beyond treatment, with initiatives aimed at supporting and engaging the patient community. As mentioned on Krystal's website, they are committed to providing support and resources for patients and caregivers. This includes patient advocacy programs and educational resources designed to improve the lives of those affected by rare dermatological diseases.

Commitment to Quality and Safety:

Given the nature of gene therapy, a strong emphasis on quality and safety is paramount. Krystal Biotech's adherence to regulatory standards and investment in manufacturing capabilities reflect this value. Their state-of-the-art manufacturing facility, coupled with rigorous quality control processes, ensures the reliability and safety of their products. The company ended 2024 with approximately $1.3 billion in cash, cash equivalents, and marketable securities, which supports their ongoing commitment to quality and safety in manufacturing and development.

Ethical Conduct and Transparency:

Operating with integrity and transparency is crucial in the pharmaceutical industry. Krystal Biotech's interactions with healthcare professionals, regulatory bodies, and the patient community likely adhere to the highest ethical standards. Their commitment to transparency is evident in their detailed financial reporting and open communication about clinical trial results. For example, Krystal Biotech actively participates in industry conferences and publishes their research findings in peer-reviewed journals. This helps to ensure that their work is subject to rigorous scrutiny and contributes to the broader scientific community.

To delve deeper into Krystal Biotech's background, explore this resource: Krystal Biotech, Inc. (KRYS): History, Ownership, Mission, How It Works & Makes Money